The Effects of Levetiracetam on Alcohol Consumption in Alcohol-Dependent Subjects: An Open Label Study

REFERENCES

• Carunchio I, Pieri M, Ciotti M T, Albo F, Zona C. Modulation of AMPA receptors in cultured cortical neurons induced by the antiepileptic drug levetiracetam. Epilepsia 2007; 48(4)654–662
   PubMed Web of Science ®Google Scholar
• Sanchis-Segura C, Borchardt T, Vengeliene V, Zghoul T, Bachteler D, Gass P, Sprengel R, Spanagel R. Involvement of the AMPA receptor GluR-C subunit in alcohol-seeking behavior and relapse. J Neurosci 2006; 26: 1231–1238
   PubMed Web of Science ®Google Scholar
• Rigo J M, Hans G, Nguyen L, Rocher V, Belachew S, Malgrange B, Leprince P, Moonen G, Selak I, Matagne A, Klitgaard H. The anti-epileptic drug levetiracetam reverses the inhibition by negative allosteric modulators of neuronal GABA- and glycine-gated currents. Br J Pharmacol 2002; 136: 659–672
   PubMed Web of Science ®Google Scholar
• Krebs M, Leopold K, Richter C, Kienast T, Hinzpeter A, Heinz A, Schaefer M. Levetiracetam for the treatment of alcohol withdrawal syndrome: an open-label pilot trial. J Clin Psychopharmacol 2006; 26: 347–349
   PubMed Web of Science ®Google Scholar
• Lamberty Y, Gower A J, Klitgaard H. The new antiepileptic drug levetiracetam normalises chlordiazepoxide withdrawal-induced anxiety in mice. Eur J Pharmacol 2002; 439(1–3)101–106
   PubMed Web of Science ®Google Scholar
• Kinrys G, Worthington J J, Wygant L, Nery F, Reese H, Pollack M H. Levetiracetam as adjunctive therapy for refractory anxiety disorders. J Clin Psychiatry 2007; 68(7)1010–1013
   PubMed Web of Science ®Google Scholar
• Papp L A. Safety and efficacy of levetiracetam for patients with panic disorder: Results of an open-label, fixed-flexible dose study. J Clin Psychiatry 2006; 67(10)1573–1576
   PubMed Web of Science ®Google Scholar
• Simon N M, Worthington J J, Doyle A C, Hoge E A, Kinrys G, Fischmann D, Link N, Pollack M H. An open-label study of levetiracetam for the treatment of social anxiety disorder. J Clin Psychiatry 2004; 65(9)1219–1222
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed Text Revision. American Psychiatric Association, Washington, DC 2000
   Google Scholar
• First M B, Spitzer R L. Structured Clinical Interview for DSM-IV Axis I. Disorders-Subject Edition (SCID-I/P, Version 2.0). Biometrics Research Department New York State Psychiatric Institute, New York 1996
   Google Scholar
• Saunders J B, Aasland O G, Babor T F, de la Fuente J R, Grant M. Development of the Alcohol Use Disorders Identification Test (AUDIT): WHO Collaborative Project on Early Detection of Persons with Harmful Alcohol Consumption–II. Addiction 1993; 88(6)791–804
   PubMed Web of Science ®Google Scholar
• Starosta A N, Leeman R F, Volpicelli J R. The BRENDA model: Integrating psychosocial treatment and pharmacotherapy for the treatment of alcohol use disorders. J Psychiatr Pract 2006; 12(2)80–89
   PubMedGoogle Scholar
• Sullivan J T, Sykora K, Schneiderman J, Naranjo C A, Sellers E M. Assessment of alcohol withdrawal: the revised clinical institute withdrawal assessment for alcohol scale (CIWA-Ar). Br J Addict 1989; 84(11)1353–1357
   PubMedGoogle Scholar
• Anton R F, Moak D H, Latham P K. The obsessive compulsive drinking scale: A new method of assessing outcome in alcoholism treatment studies. Arch Gen Psychiatry 1996; 53(3)225–231
   PubMed Web of Science ®Google Scholar
• Sobell L C, Sobell M B. Timeline follow-back: a technique for assessing self-reported alcohol consumption, in Measuring alcohol consumption: Psychosocial and biochemical methods, R Z Litten, J P Allen. Humana Press, Totowa, N.J 1992
   Google Scholar
• Cacciola J S, Alterman A I, McLellan A T, Lin Y T, Lynch K G. Initial evidence for the reliability and validity of a “Lite” version of the Addiction Severity Index. Drug Alcohol Depend 2007; 87(2-3)297–302
   PubMed Web of Science ®Google Scholar
• McNair D M, Lorr M, Droppelman L F. POMS Manual-Profile of Mood Questionnaire. 1992, San Diego
   Google Scholar
• Spritzer K L, Hays R D. MOS Sleep Scale: A Manual for Use and Scoring, Version 1.0. Los Angeles, CA 2003
   Google Scholar
• Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol 1959; 32(1)50–55
   PubMed Web of Science ®Google Scholar
• Hamilton M. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 1967; 6(4)278–296
   PubMedGoogle Scholar
• SAS Institute Inc. SAS9.1. Cary, N.C. 2002
   Google Scholar
• Mueller T I, Stout R L, Rudden S, Brown R A, Gordon A, Solomon D A, Recupero P R. A double-blind, placebo-controlled pilot study of carbamazepine for the treatment of alcohol dependence. Alcohol Clin Exp Res 1997; 21: 86–92
   PubMed Web of Science ®Google Scholar
• Croissant B, Scherle T, Diehl A, Heinz A, Mann K. Oxcarbazepine in alcohol relapse prevention–a case series. Pharmacopsychiatry 2004; 37: 306–307
   PubMed Web of Science ®Google Scholar
• Longo L P, Campbell T, Hubatch S. Divalproex sodium (Depakote) for alcohol withdrawal and relapse prevention. J Addict Dis 2002; 2: 55–64
   Web of Science ®Google Scholar
• Salloum I M, Cornelius J R, Daley D C, Kirisci L, Himmelhoch J M, Thase M E. Efficacy of valproate maintenance in patients with bipolar disorder and alcoholism: a double-blind placebo-controlled study. Arch Gen Psychiatry 2005; 62: 37–45
   PubMed Web of Science ®Google Scholar
• Johnson B A, Ait-Daoud N, Bowden C L, Di Clemente C C, Roache J D, Lawson K, Javors M A, Ma J Z. Oral topiramate for treatment of alcohol dependence: a randomised controlled trial. Lancet 2003; 361: 1677–1685
   PubMed Web of Science ®Google Scholar
• Johnson B A, Rosenthal N, Capece J A, Wiegand F, Mao L, Beyers K, McKay A, Ait-Daoud N, Anton R F, Ciraulo D A, Kranzler H R, Mann K, O'Malley S S, Swift R M. Topiramate for Alcoholism Advisory Board; Topiramate for Alcoholism Study Group. Topiramate for treating alcohol dependence: a randomized controlled trial. JAMA 2007; 298(14)1641–1651
   PubMed Web of Science ®Google Scholar
• Gomer B, Wagner K, Frings L, Saar J, Carius A, Härle M, Steinhoff B J, Schulze-Bonhage A. The influence of antiepileptic drugs on cognition: a comparison of levetiracetam with topiramate. Epilepsy Behav 2007; 10(3)486–494
   PubMed Web of Science ®Google Scholar
• Patsalos P N. Clinical pharmacokinetics of levetiracetam. Clin Pharmacokinet 2004; 43(11)707–724
   PubMed Web of Science ®Google Scholar